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 effectiveness for lowering IOP compared with latanoprost 0.005% (w/v) and travo-
prost 0.004% (w/v).
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Objectives: To compare the cost-effectiveness for different therapies to Wet Age-
Related Maculare Degeneration (wAMD) MethOds: Literature Review: Several 
Database, such as Pubmed, Web of Science, Elsevier, Medline were searched using 
16 codes. We applied inclusion criteria to screen the literature. Randomized con-
trolled trials (RCTs), Controlled Clinical Trials (CCTs), and Controlled Before-and-
After studies were selected. This study focus on three commonly interventions to 
wAMD: Best Supportive Case (BSC), PhotoDynamic Therapy (PDT), and Ranibizumab 
therapy. Cost-effectiveness analysis (CEA), cost-utility analysis (CUA), and incremen-
tal analysis were conducted. Results: Compare with BSC and PDT, Ranibizumab 
therapy was more effective in wAMD treatment in different countries. From social 
perspective, Ranibizumab therapy was also more cost-effectiveness than BAC and 
PDT either in 5 years or in 10 years. However, from third-payer perspective, incre-
mental cost-effectiveness ratio (ICER) between Ranibizumab and BSC, Ranibizumab 
and PDT, varied in different countries. Frequency and duration of Ranibizumab 
usage may be key determinants of ICER. cOnclusiOns: Ranibizumab therapy have 
better clinical effect than BSC and PDT in wAMD treatment. Ranibizumab is also 
more cost-effectiveness than BSC and PDT from social perspective in long term. 
It may be related to the highly indirect cost of wAMB. However, from third-payer 
perspective, Ranibizumab may be good cost-effectiveness. Price and quantity of 
Ranibizumab in therapy influenced its cost-effectiveness. More research based on 
varied price and different drug usage in Ranibizumab therapy should be conducted 
before it were paid.
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Objectives: To evaluate the cost-effectiveness of the off-label used bevacizumab 
versus ranibizumab for patients with neovascular age-related macular degenera-
tion (AMD) in China. MethOds: Two different Markov models were used separately 
to compare cost per quality-adjusted life year (QALY) of four strategies defined by 
drug (bevacizumab or ranibizumab) and dosing regimen (monthly or as needed) 
in patients with neovascular AMD in China’s health care system. The VA Range 
model defines the health states using visual acuity (VA), while the VA Change model 
defines the health states according to the degree of VA changes from the time when 
entering the model. Both models used a life time horizon with a cycle length of 3 
months. Clinical data used in the models primarily came from the Comparison of 
AMD Treatment Trial (CATT), while the costs came from the financial department of 
a tertiary hospital in Beijing. Results: In the base-case analyses, the bevacizumab 
as needed strategy had slightly lower QALYs (17.479 QALYs and 15.917 QALYs in 
the VA Range model and the VA Change model, respectively) but at much lower 
costs (CN¥88,341 and CN¥79,967 in the VA Range model and the VA Change model, 
respectively) compared with the other three strategies. In probabilistic sensitivity 
analyses in both models, the probabilities of bevacizumab strategies being more 
cost-effective than ranibizumab strategies exceeded 99% if the willingness-to-pay 
(WTP) threshold for a QALY was less than CN¥120,000. When the threshold was less 
than CN¥90,000 per QALY, bevacizumab as needed was the most cost-effective alter-
native. cOnclusiOns: The bevacizumab as needed strategy was the most cost-
effective strategy compared with the ranibizumab strategies in treating patients 
with neovascular AMD, if the WTP threshold is below CN¥90,000 per QALY in China. 
This much cheaper treatment can substantially reduce the burden to the Chinese 
aging society.
PSS9
CoSt utiLity AnALySiS of uStekinumAB for the treAtment of 
moderAte to Severe ChroniC PLAque PSoriASiS in thAiLAnd
Tangwongsiri D.1, Leartsakulpanitch J.2
1Janssen-Cilag (Thailand) Limited, Bangkok, Thailand, 2Janssen Asia Pacific, Singapore
Objectives: To evaluate the cost-utility of ustekinumab versus infliximab and 
etanercept, the only biologic agents available for psoriasis in Thailand, among 
adults with moderate-to-severe plaque psoriasis who fail to respond systemic 
therapies and meet criteria based on the biologic guideline for psoriasis in 
Thailand. MethOds: The published ‘York psoriasis model’ was modified based 
on the current treatment algorithm and criteria of biologics use in Thai psoriasis 
guideline. Short-term trial efficacy data (PASI response) from a published network 
meta-analysis of RCT was used to model the response of patients to initial treat-
ment. Beyond the initial period, the model extrapolated results up to 10 years with 
annual risk of treatment withdrawal. The DLQI scores from ustekinumab trials were 
transposed into utility gain (EQ5D) and applied to PASI response level regardless of 
the treatment received. Both direct medical cost and non-medical cost including 
biologic acquisition, monitoring lab tests, outpatient visit, and traveling expense 
were calculated. The amount of resource consumption was estimated by experts’ 
opinions and literatures. Cost and outcomes were discounted at 3%. One-way 
and probabilistic sensitivity analysis was conducted to assess the model robust-
ness. Results: Over the 10-year time horizon, ustekinumab showed the lowest 
mean annual cost of 507,502 baht followed by etanercept (582,881 baht) and inflixi-
mab (585,462 baht) respectively. The mean QALY gain of ustekinumab was higher 
than etanercept (0.1448 vs. 0.1392) but lower than infliximab (0.1448 vs. 0.1564). 
Considering the cost-utility ratio, ustekinumab was dominant compared to etaner-
Preschool children with dental caries is associated with high treatment costs and 
the number of cavities play an important role in determination of costs. Therefore, 
preschool children should pay attention to oral hygiene and form good habits to 
prevent dental caries.
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Objectives: To explore the burden of wet age-related macular degeneration 
(WAMD) in China. MethOds: Multi-center, retrospective and cross-sectional inves-
tigation was adopted. Beijing, Chengdu, Guangzhou and Shanghai were selected 
as sample cities, and several hospitals were involved in each city. Patients were 
selected according to inclusive and exclusive criteria, and they were divided into 5 
groups, i.e., photodynamic therapy (PDT), photocoagulation therapy, surgery therapy, 
joint therapy and support therapy groups. Direct cost, indirect cost and burden of 
disease (BOD) were studied. Results: 417 eligible patients were acquired, males 
and females accounted for 51.32% and 48.68% respectively. Burden of WAMD for 
per eye per year was 4857 USD. Burden of WAMD of whole disease course for each 
eye was 33999 USD. The proportion of direct medical cost in BOD was only 26.35%, 
however, that of indirect cost reached 68.58%. cOnclusiOns: The burden of 
WAMD is relatively high in China, it should be paid more attention by stakehold-
ers. Although new diagnostic and therapeutic methods may raise direct medical 
cost, they may reduce total burden of  WAMD more, which shows the advantage for 
new technologies. WAMD guideline will be beneficial to both patients and direct 
medical cost management. Targeting young patients as a priority of intervention 
will help to reduce total social burden of  WAMD.
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Objectives: Glaucoma is a major cause of visual impairment and a chronic dis-
ease requiring treatment for lifetime. Management of intraocular pressure (IOP) 
is the main focus of treatment, and many pharmacological treatment agents are 
recommended and available in Korea. This study was conducted to facilitate effi-
cient allocation of limited resources amongst various pharmacological agents. The 
objective of this study was to evaluate costs and effectiveness of two most com-
monly used drugs in Korea which are latanoprost and dorzolamide/timolol fixed 
combination. MethOds: A decision analytic model was developed from a payer 
perspective to evaluate clinical effectiveness, costs and utility values of latanoprost 
and dorzolamide/timolol fixed combination. The model was constructed based on a 
one-month cycle with a time horizon of one year. The treatment success to meas-
ure effectiveness was defined as achieving a ≥ 20% reduction IOP from baseline. 
Costs of medication, diagnostic fees, physician and pharmacy visitation fees, and 
surgery fees were included in the study. Utility values according to the severity 
of glaucoma were also incorporated in the model. Treatment success and failure 
rates as well as utility for each health state were obtained from previously pub-
lished literature and local market analysis data. Cost information was obtained 
from Korea-specific data sources. The result of this study was expressed in an 
incremental cost-effectiveness ratio (ICER). One-way sensitivity analysis was con-
ducted to evaluate different clinical parameters. Results: The final effectiveness 
values for latanoprost and dorzolamide/timolol fixed combination were 0.9098 and 
0.9089 in quality-adjusted life year (QALY), and the final costs were 550,737 KRW 
and 534,789 KRW respectively. Latanoprost displayed an ICER of 17,500,246 KRW/
QALY compared to dorzolamide/timolol fixed combination. cOnclusiOns: Under 
the currently implied ICER threshold in Korea, latanoprost can be interpreted as a 
cost-effective treatment option compared to dorzolamide/timolol fixed combination 
on the treatment of glaucoma.
PSS6
A ProSPeCtive PhArmACoeConomiC Study of BiLAterAL 
ProStAgLAndin/ ProStAmide therAPy for Lowering intrAoCuLAr 
PreSSure (ioP) in the PAtientS in South indiA
Addanki D.
Raghavendra Institute of Pharmaceutical Education and Research, Anantapur, India
Objectives: To determine monthly cost and cost effectiveness of bilateral prosta-
glandin/ prostamide therapy for lowering intraocular pressure (IOP) in patients tak-
ing bimatoprost (0.03%), latanoprost (0.005%), or travoprost (0.004%). MethOds: 
This prospective pharmacoeconomic study evaluated the direct cost and cost effec-
tiveness of prostaglandin/prostamide therapy for reduction of IOP in patients with 
glaucoma or ocular hypertension. Drops in five new 2.5-mL bottles were counted 
and then averaged for each drug. Average retail price was determined by surveys 
of pharmacies. Drop count, average retail price, average wholesale price, and IOP 
reduction data were used to compute annual cost, and cost effectiveness (annual 
cost-per-mm Hg of IOP reduction) of the three drugs. Results: Drops per 2.5-mL 
bottle averaged 113 for bimatoprost 0.03% (w/v), 84 for latanoprost 0.005% (w/v), and 
83 for travoprost 0.004% (w/v). Average retail cost (2005) per bottle was INR.3,080 
for bimatoprost 0.03% (w/v), INR.2,715 for latanoprost 0.005% (w/v), and INR.2,920 
for travoprost 0.004% (w/v). The monthly retail cost of bilateral therapy was 
INR.1,668 for bimatoprost 0.03% (w/v), INR.1,970 for latanoprost 0.005% (w/v), and 
INR.2,167 for travoprost 0.004% (w/v). Cost effectiveness ranges were INR.2,508 
to INR.2,860 per mm Hg reduction in IOP per year for bimatoprost, 0.03% (w/v), 
INR.2,948 to INR.3,960 per mm Hg for latanoprost 0.005% (w/v), and INR.3,256 to 
INR.3,696 per mm Hg for travoprost 0.004% (w/v). cOnclusiOns: Bimatoprost 
0.03% (w/v) had the lowest monthly and annual costs and the greatest cost 
